Submitted by kBLASTER Team on
posted in The National Law Review
Commentary on FDA's final guidance titled The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notification [510(k)] discussing use of primary predicate and "split predicate" 510(k) submissions, as described in a previous posting.
